id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-302756-343y63e5	Thachil, J	Understanding the COVID‐19 coagulopathy spectrum	2020-05-21		.txt	text/plain	2229	138	42	From a laboratory perspective, this hypercoagulability is reflected in the marked elevation of the fibrinolytic marker, D-dimer, in almost all hospitalised COVID-19 patients [7] . Platelet counts are increased in these patients in the initial stages (uncommonly reported in patients with infectious diseases) and are almost never severely low, even in critically ill COVID-19 patients [18] . In severely ill patients, the pulmonary coagulation system becomes markedly activated. These include: should all patients hospitalised with severe COVID-19 be treated empirically with therapeutic anticoagulation until venous thromboembolism is discounted? High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Incidence of thrombotic complications in critically ill ICU patients with COVID-19 COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure.	./cache/cord-302756-343y63e5.txt	./txt/cord-302756-343y63e5.txt